Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related ...

Novavax COVID vaccine shows strong efficacy The biotechnology company announced Monday that its stage three clinical trial showed overall efficacy of 90.4% against COVID-19.

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Novavax ( ($NVAX) ) has risen by 24.00%. Read on to learn why. Novavax has experienced a notable 24.00% increase in its stock price over the past ...

The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions -- by its April 1 ...